Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


Eiger Bio's Avexitide Reduces Glucose Infusion Requirements To Maintain Normal Glucose Levels In Neonates, Infants


Benzinga | Jun 28, 2021 10:53AM EDT

Eiger Bio's Avexitide Reduces Glucose Infusion Requirements To Maintain Normal Glucose Levels In Neonates, Infants

* Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) announced an oral poster presentation of Phase 2 study results of Avexitide in congenital hyperinsulinism (HI) at the American Diabetes Association Scientific Session.

* HI is an ultra-rare, life-threatening pediatric disorder of persistent hypoglycemia that results in irreversible brain damage in up to 50% of children.

* Avexitide significantly reduced glucose infusion rate (GIR) when evaluated across dose levels, with dose-dependent improvements observed.

* Avexitide 100, 200, and 1,000 pmol/kg/min ascending doses demonstrated 1.3 (15%), 2.9 (24%), and 4.3 (56%) mg/kg/min reductions in GIR relative to placebo, respectively, and entirely abolished the glucose requirement in 50% of patients at the top dose.

* Avexitide was well-tolerated in this study. Adverse events were typically mild in severity and transient, and there were no serious adverse events.

* The company plans to be Phase 3 ready as early as 2022.

* Price Action: EIGR shares are up 7.9% at $9.36 during the market session on the last check Monday.







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC